Abcam (ABC)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 23.7 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 5.80 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Jun | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Last ex-div: 20th Mar, paid: 19th Apr more... Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | +47.0% | |||||||||
FINANCIAL BRIEF: For the six months ended 31 December 2012, Abcam Plc revenues increased 28% to L57.3M. Net income increased 18% to L15.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and Development Expense increase from L1.5M to L4.2M (expense), Interest Receivable decrease of 78% to L59K (income). Dividend per share remained flat at L0.02. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 1 | 0 | 2 | 0 | 3 |
Abcam Plc produces and distributes research-grade antibodies and associated products. Headquartered in Cambridge, the United Kingdom, the company distributes its products thru an online catalog.
Directors: Jonathan Milner (CEO) , Jeffrey Iliffe (CFO) , Jim Warwick (COO) , Ed Ralph (CIO) , Mark Bushfield (Other) , Jane Cooke (Other) , Philippe Cotrel (Other) ,
No. of Employees: 680 No. of Shareholders: n/a
| Last Annual | June 30th, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 198,595,024 |
| Free Float | 152.5m (76.8%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share, FTSE Aim 100, FTSE Aim UK 50, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | 330 Cambridge Science Park MILTON ROAD, CAMBRIDGE, CB4 0FL, United Kingdom |
| Web | http://www.abcam.com/ |
| Phone | +44 1223 696000 |
| Contact | Eddie Powell (Fin. Dir.) |
| Registrar | Capita Registrars |
| Auditors | Deloitte LLP |
| Wed 4:12pm | Director/PDMR Shareholding |
| 16th May | Director/PDMR Shareholding |
| 4th Apr | Holding(s) in Company |
| 4th Apr | Holding(s) in Company |
| 2nd Apr | Total Voting Rights |
| 2nd Apr | Holding(s) in Company |
Recent ↓
